Table 1. Characteristic information of the study populations.

Study	Controls	Lung cancer patients
		All	AD10	SQ11
ICR1	5200	1952	465	611
MDACC2	1134	1150	619	306
IARC3	3791	2533	517	911
NCI4	5736	5713	1841	1447
Toronto5	499	331	90	50
GLC6	478	481	186	97
TRICL7	16838	12160	3718	3422
Harvard8	970	984	597	216
deCODE9	26380	1319	547	259
All combined	44188	14463	4862	3897

¹ICR: the Institute of Cancer Research Genome-wide Association Study, UK;

²MDACC: the MD Anderson Cancer Center Genome-wide Association Study, US;

³IARC: the International Agency for Research on Cancer Genome-wide Association Study, France;

⁴NCI: the National Cancer Institute Genome-wide Association Study, US;

⁵Toronto: the Lunenfeld-Tanenbaum Research Institute Genome-wide Association Study, Toronto, Canada;

⁶GLC: German Lung Cancer Study, Germany;

⁷TRICL: GWASs datasets combined by six GWASs of ICR, MDACC, IARC, NCI, Toronto and GLC;

⁸Harvard: Harvard Lung Cancer Study, US;

⁹deCODE: Icelandic Lung Cancer Study, Iceland;

¹⁰AD: adenocarcinoma;

¹¹SQ: squamous cell carcinoma.